Implementing Scale Dependencies into Computational Bioreactor Models to Facilitate Predictions of Protein Glycosylation in Different Environments

This project will deliver an interoperable simulation platform integrating spatially resolved CFD flow fields, cell kinetics, and mechanistic models of intracellular glycosylation.
Categories
Drug substance
Process control
Data

Industry Need

Although significant progress has been made in modeling glycosylation at small scales, scaling up to production bioreactors introduces complex gradients in nutrients, oxygen, pH, and metabolite concentrations that affect cellular performance, ultimately impacting product properties including glycosylation. This project addresses a critical need in upstream bioprocess modeling: predicting the impact of hydrodynamic heterogeneity on glycosylation outcomes during CHO based protein production for different scales and bioreactor configurations.

Approach

This proposal brings together researchers in mammalian hydrodynamics and systems biology of glycosylation to deliver an interoperable simulation platform integrating spatially resolved CFD flow fields, cell kinetics, and mechanistic models of intracellular glycosylation. The platform will help NIIMBL partners build digital twins, accelerate process development, validate glycosylation robustness, and inform scale-up decisions. This platform can be extended in the future to include automated CFD routines and machine learning-assisted parameter optimization. The tool will support both research and industrial applications, advancing NIIMBL’s mission to accelerate biomanufacturing innovation.

Impacts

The platform will help NIIMBL partners build digital twins, accelerate process development, validate glycosylation robustness, and inform scale-up decisions.

This platform can be extended in the future to include automated CFD routines and machine learning-assisted parameter optimization. The tool will support both research and industrial applications, advancing NIIMBL’s mission to accelerate biomanufacturing innovation.

Value Statement/Outcomes

This project seeks to demonstrate a computational bioreactor modeling platform that improves scale-up predictions for drug companies, resulting in quality benefits across large-scale manufacturing.

Outputs/Deliverables

Deliverables include Python software packages, step-by-step example workflows, training materials, and graphical output of key metrics (e.g., glycan distribution over time, pH and oxygen maps).

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

The Ohio State University

The Ohio State University

Participating Organizations

AstraZeneca

AstraZeneca

Boehringer Ingelheim

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers Squibb

EMD Millipore Corporation

EMD Millipore Corporation

Federal Stakeholder:  National Institute of Standards and Technology

Federal Stakeholder: National Institute of Standards and Technology

Johns Hopkins University

Johns Hopkins University

Pfizer, Inc.

Pfizer, Inc.

Sanofi

Sanofi